{"id":917444,"date":"2025-12-08T12:40:34","date_gmt":"2025-12-08T17:40:34","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/co-diagnostics-jv-cosara-to-participate-at-virocon-2025-in-pune-india\/"},"modified":"2025-12-08T12:40:34","modified_gmt":"2025-12-08T17:40:34","slug":"co-diagnostics-jv-cosara-to-participate-at-virocon-2025-in-pune-india","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/co-diagnostics-jv-cosara-to-participate-at-virocon-2025-in-pune-india\/","title":{"rendered":"Co-Diagnostics JV, CoSara, to Participate at VIROCON 2025 in Pune, India"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n Ongoing Phase II preclinical study data for Co-Dx PCR MTB and HPV tests support advancement to clinical performance testing<\/i>\n <\/p>\n

\n
\n SALT LAKE CITY<\/span>
\n <\/span>, Dec. 9, 2025<\/span><\/span> \/PRNewswire\/ —\u00a0Co-Diagnostics, Inc.<\/a>\u00a0(Nasdaq: CODX)<\/b>\u00a0(“Co-Dx” or “the Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that CoSara Diagnostics Pvt. Ltd. (“CoSara”), the joint venture (“JV”) between Ambalal Sarabhai Enterprises Limited (ASE Group) and Co-Dx, will participate and host a booth at VIROCON 2025, taking place December 8-10<\/span> at the Conrad Hotel in Pune<\/span>, Maharashtra, India<\/span>.<\/p>\n

\n

\n
\n \"(PRNewsfoto\/Co-Diagnostics)\"
\n <\/a>\n <\/p>\n<\/p><\/div>\n

CoSara is currently supporting the second phase of the Company’s preclinical studies for the Co-Dx PCR MTB (tuberculosis) test and Co-Dx PCR HPV multiplex test on the Co-Dx PCR point-of-care (PoC) platform*. Phase I of the MTB test studies included 354 clinical specimens from sputum and tongue swabs to provide early sensitivity and specificity assessments, while Phase II has evaluated 211 sputum specimens in a comparison evaluation against other tests to establish concordance for Mycobacterium tuberculosis<\/i> detection. The studies are being conducted in preparation of advancement to clinical performance testing, required by Indian regulatory authorities prior to submission.<\/p>\n

Phase I of the preclinical studies for the 8-type HPV multiplex test, designed to identify the presence of eight different human papillomavirus genotypes, evaluated 286 clinical specimens to validate and optimize the Co-Primers\u00ae test chemistry for HPV. Three of the eight genotypes are classified as high-risk for cancer, and in Phase II, 53 specimens have been analyzed to date to facilitate the differential detection of the three high-risk HPV genotypes as the application algorithm continues to be trained, refined and optimized.<\/p>\n

The Company believes that data gathered thus far in the preclinical studies for both tests support advancement to clinical performance testing, as part of the pathway to regulatory submissions.<\/p>\n

Attendees interested in learning more about CoSara products, including the TB and HPV tests on the Company’s upcoming Co-Dx PCR platform, are encouraged to stop by at VIROCON 2025. CoSara will be available for meetings and interactions at CoSara’s booth.<\/p>\n

\n VIROCON 2025<\/a>\u00a0is organized by the India Council of Medical Research – National Institute of Virology (“ICMR-NIV”), with this year’s theme being “Changing Landscape in Human, Animal, and Plant Viruses: Bridging Basic Science, Innovations and Public Health.” The conference is expected to provide a platform for productive scientific deliberations and collaborations aimed at developing solutions to contain the viral epidemics that threaten human, animal, plant, aquatic and environmental health.<\/p>\n

\n
\n *The Co-Dx PCR platform (including the PCR Home\u2122, PCR Pro\u2122, mobile app, and all associated tests) is subject to review by the FDA and\/or other regulatory bodies and is not yet available for sale. <\/u>
\n <\/i>\n <\/p>\n

\n About Co-Diagnostics, Inc.:
<\/b>Co-Diagnostics, Inc., a Utah<\/span> corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company’s technologies are utilized for tests that are designed to detect and\/or analyze nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory review and not currently for sale) and to identify genetic markers for use in applications other than infectious disease.<\/p>\n

\n Forward-Looking Statements:
<\/b>
\n This press release contains forward-looking statements. Forward-looking statements can be identified by words such as “believes,” “expects,” “estimates,” “intends,” “may,” “plans,” “will” and similar expressions, or the negative of these words. Forward-looking statements include statements made with respect to our Co-Dx PCR platform and tests, including statements about potential or future clinical performance studies, regulatory submissions, product performance, market opportunities, or commercialization efforts related to the Co-Dx PCR platform and associated tests. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances. Actual results may differ materially from those contemplated or anticipated by such forward-looking statements. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. There can be no assurance that any of the anticipated results will occur on a timely basis or at all due to certain risks and uncertainties, a discussion of which can be found in our Risk Factors disclosure in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 27, 2025<\/span>, and in our other filings with the SEC. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.<\/i>\n <\/p>\n

\n \"Cision\" View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/co-diagnostics-jv-cosara-to-participate-at-virocon-2025-in-pune-india-302635378.html<\/a><\/p>\n

SOURCE Co-Diagnostics<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire Ongoing Phase II preclinical study data for Co-Dx PCR MTB and HPV tests support advancement to clinical performance testing SALT LAKE CITY , Dec. 9, 2025 \/PRNewswire\/ —\u00a0Co-Diagnostics, Inc.\u00a0(Nasdaq: CODX)\u00a0(“Co-Dx” or “the Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that CoSara Diagnostics Pvt. Ltd. (“CoSara”), the joint venture (“JV”) between Ambalal Sarabhai Enterprises Limited (ASE Group) and Co-Dx, will participate and host a booth at VIROCON 2025, taking place December 8-10 at the Conrad Hotel in Pune, Maharashtra, India. CoSara is currently supporting the second phase of the Company’s preclinical studies for the Co-Dx PCR MTB (tuberculosis) test and Co-Dx PCR HPV multiplex test on the … <\/p>\n

Continue reading “Co-Diagnostics JV, CoSara, to Participate at VIROCON 2025 in Pune, India”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-917444","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCo-Diagnostics JV, CoSara, to Participate at VIROCON 2025 in Pune, India - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/co-diagnostics-jv-cosara-to-participate-at-virocon-2025-in-pune-india\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Co-Diagnostics JV, CoSara, to Participate at VIROCON 2025 in Pune, India - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire Ongoing Phase II preclinical study data for Co-Dx PCR MTB and HPV tests support advancement to clinical performance testing SALT LAKE CITY , Dec. 9, 2025 \/PRNewswire\/ —\u00a0Co-Diagnostics, Inc.\u00a0(Nasdaq: CODX)\u00a0(“Co-Dx” or “the Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that CoSara Diagnostics Pvt. Ltd. (“CoSara”), the joint venture (“JV”) between Ambalal Sarabhai Enterprises Limited (ASE Group) and Co-Dx, will participate and host a booth at VIROCON 2025, taking place December 8-10 at the Conrad Hotel in Pune, Maharashtra, India. CoSara is currently supporting the second phase of the Company’s preclinical studies for the Co-Dx PCR MTB (tuberculosis) test and Co-Dx PCR HPV multiplex test on the … Continue reading "Co-Diagnostics JV, CoSara, to Participate at VIROCON 2025 in Pune, India"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/co-diagnostics-jv-cosara-to-participate-at-virocon-2025-in-pune-india\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-08T17:40:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1856437\/Co_Diagnostics_New_Logo_v1.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/co-diagnostics-jv-cosara-to-participate-at-virocon-2025-in-pune-india\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/co-diagnostics-jv-cosara-to-participate-at-virocon-2025-in-pune-india\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Co-Diagnostics JV, CoSara, to Participate at VIROCON 2025 in Pune, India\",\"datePublished\":\"2025-12-08T17:40:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/co-diagnostics-jv-cosara-to-participate-at-virocon-2025-in-pune-india\\\/\"},\"wordCount\":782,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/co-diagnostics-jv-cosara-to-participate-at-virocon-2025-in-pune-india\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1856437\\\/Co_Diagnostics_New_Logo_v1.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/co-diagnostics-jv-cosara-to-participate-at-virocon-2025-in-pune-india\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/co-diagnostics-jv-cosara-to-participate-at-virocon-2025-in-pune-india\\\/\",\"name\":\"Co-Diagnostics JV, CoSara, to Participate at VIROCON 2025 in Pune, India - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/co-diagnostics-jv-cosara-to-participate-at-virocon-2025-in-pune-india\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/co-diagnostics-jv-cosara-to-participate-at-virocon-2025-in-pune-india\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1856437\\\/Co_Diagnostics_New_Logo_v1.jpg\",\"datePublished\":\"2025-12-08T17:40:34+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/co-diagnostics-jv-cosara-to-participate-at-virocon-2025-in-pune-india\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/co-diagnostics-jv-cosara-to-participate-at-virocon-2025-in-pune-india\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/co-diagnostics-jv-cosara-to-participate-at-virocon-2025-in-pune-india\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1856437\\\/Co_Diagnostics_New_Logo_v1.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1856437\\\/Co_Diagnostics_New_Logo_v1.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/co-diagnostics-jv-cosara-to-participate-at-virocon-2025-in-pune-india\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Co-Diagnostics JV, CoSara, to Participate at VIROCON 2025 in Pune, India\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Co-Diagnostics JV, CoSara, to Participate at VIROCON 2025 in Pune, India - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/co-diagnostics-jv-cosara-to-participate-at-virocon-2025-in-pune-india\/","og_locale":"en_US","og_type":"article","og_title":"Co-Diagnostics JV, CoSara, to Participate at VIROCON 2025 in Pune, India - Market Newsdesk","og_description":"PR Newswire Ongoing Phase II preclinical study data for Co-Dx PCR MTB and HPV tests support advancement to clinical performance testing SALT LAKE CITY , Dec. 9, 2025 \/PRNewswire\/ —\u00a0Co-Diagnostics, Inc.\u00a0(Nasdaq: CODX)\u00a0(“Co-Dx” or “the Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that CoSara Diagnostics Pvt. Ltd. (“CoSara”), the joint venture (“JV”) between Ambalal Sarabhai Enterprises Limited (ASE Group) and Co-Dx, will participate and host a booth at VIROCON 2025, taking place December 8-10 at the Conrad Hotel in Pune, Maharashtra, India. CoSara is currently supporting the second phase of the Company’s preclinical studies for the Co-Dx PCR MTB (tuberculosis) test and Co-Dx PCR HPV multiplex test on the … Continue reading \"Co-Diagnostics JV, CoSara, to Participate at VIROCON 2025 in Pune, India\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/co-diagnostics-jv-cosara-to-participate-at-virocon-2025-in-pune-india\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-08T17:40:34+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1856437\/Co_Diagnostics_New_Logo_v1.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/co-diagnostics-jv-cosara-to-participate-at-virocon-2025-in-pune-india\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/co-diagnostics-jv-cosara-to-participate-at-virocon-2025-in-pune-india\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Co-Diagnostics JV, CoSara, to Participate at VIROCON 2025 in Pune, India","datePublished":"2025-12-08T17:40:34+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/co-diagnostics-jv-cosara-to-participate-at-virocon-2025-in-pune-india\/"},"wordCount":782,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/co-diagnostics-jv-cosara-to-participate-at-virocon-2025-in-pune-india\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1856437\/Co_Diagnostics_New_Logo_v1.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/co-diagnostics-jv-cosara-to-participate-at-virocon-2025-in-pune-india\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/co-diagnostics-jv-cosara-to-participate-at-virocon-2025-in-pune-india\/","name":"Co-Diagnostics JV, CoSara, to Participate at VIROCON 2025 in Pune, India - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/co-diagnostics-jv-cosara-to-participate-at-virocon-2025-in-pune-india\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/co-diagnostics-jv-cosara-to-participate-at-virocon-2025-in-pune-india\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1856437\/Co_Diagnostics_New_Logo_v1.jpg","datePublished":"2025-12-08T17:40:34+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/co-diagnostics-jv-cosara-to-participate-at-virocon-2025-in-pune-india\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/co-diagnostics-jv-cosara-to-participate-at-virocon-2025-in-pune-india\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/co-diagnostics-jv-cosara-to-participate-at-virocon-2025-in-pune-india\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1856437\/Co_Diagnostics_New_Logo_v1.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1856437\/Co_Diagnostics_New_Logo_v1.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/co-diagnostics-jv-cosara-to-participate-at-virocon-2025-in-pune-india\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Co-Diagnostics JV, CoSara, to Participate at VIROCON 2025 in Pune, India"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/917444","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=917444"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/917444\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=917444"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=917444"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=917444"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}